SKSibel Yucel Kocak

Sibel Yucel Kocak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sibel Yucel Kocak has a total of 191 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An International Multicentre Study of Haemodialysis Patients' Knowledge of Safe Self‐Disconnection From the Dialysis Machine in Emergencies

    by Nurten Ozen, Savaş Ozturk, Cansu Polat Dunya, Tomasz Hryszko, Filipa Fernandes, Stavroula Vovlianou, Joris I. Rotmans, Kristine Lindhard, Edwin Castillo Velarde, Ergun Parmaksiz, et al.

    Background: Although international guidelines recommend that patients be trained in emergency self‐disconnection procedures from the dialysis machine, little is known about patients' knowledge and procedural accuracy regarding this practice. Objective: This study aimed to evaluate the knowledge of people receiving haemodialysis and their ability to correctly identify the steps required to disconnect themselves from the dialysis machine in an emergency, safely. Methods: This international multicentre descriptive study was conducted between September 2025 and January 2026 in 10 dialysis centres across six countries: Türkiye, Denmark, Greece, Portugal, Poland and Peru. Adult patients receiving maintenance haemodialysis for at least 3 months were eligible to participate. Data were collected using a participant information form and a self‐disconnection checklist consisting of two sections evaluating preparation knowledge and procedural steps. Descriptive statistics were used to summarise the data. Results: Of the 626 people receiving haemodialysis included in the study, 125 (20.0%) had received training on self‐disconnection from the dialysis machine (Türkiye, Peru, Greece, and Denmark). Overall, 22.4% of patients reported knowing how to disconnect themselves from the dialysis machine in an emergency. According to the checklist evaluation, 40.3% of patients correctly identified the first stage of the procedure, and 38.3% correctly identified the second stage. Conclusion: A substantial gap exists between perceived knowledge and actual procedural competence regarding emergency self‐disconnection among people receiving haemodialysis. These findings highlight the need for structured education, simulation‐based training and standardised protocols to improve disaster preparedness and patient safety in dialysis units. ClinicalTrials.gov: NCT07412834.

  • Open Access

    Real-world epidemiology and renal outcomes of ADPKD in Türkiye: the PKD-TURK cohort

    by Serpil Muge Deger, Necmi Eren, Sibel Yucel Kocak, Gulay Ulusal Okyay, Beyhan Güvercin, Abdulmecit Yildiz, Halime Soyak Kabaca, Sabahat Alisir Ecder, Tahsin Karaaslan, Ayca Inci, et al.

    Introduction: Real-world epidemiological and longitudinal outcome data on autosomal dominant polycystic kidney disease (ADPKD) remain limited in underrepresented populations, including Türkiye. We aimed to characterize the epidemiology, regional distribution, and renal outcomes of ADPKD in a large multicenter national cohort. Methods: In this retrospective multicenter study, adult patients with ADPKD were identified across tertiary nephrology centers in six regions of Türkiye (2010–2025). Study-based prevalence was calculated using Turkish Statistical Institute population data. Longitudinal renal outcomes were evaluated using serial eGFR measurements and Cox regression models identified predictors of ≥ 40% eGFR decline. Results: A total of 2361 patients were included (mean age 38.6 ± 14 years; 51.8% female). Median province-level study-based prevalence was 3.86 per 100,000 population (IQR 2.92–5.49), with substantial regional variation, highest in the Black Sea region (13.46 per 100,000). Study-based prevalence increased significantly over time (annual percent change 14.4%; 95% CI 13.1–15.6; p < 0.001). During a median follow-up of 6 years, 23.9% experienced a ≥ 40% eGFR decline and 10.5% progressed to kidney failure (eGFR < 15 ml/min/1.73m2). Median annual eGFR decline was − 3.33 mL/min/1.73 m²/year. In multivariable analysis, age (adjusted HR 1.02; 95% CI 1.00–1.03; p = 0.010) and hypertension (adjusted HR 2.33; 95% CI 1.25–4.32; p = 0.007) were independently associated with renal progression, whereas tolvaptan use was associated with a lower risk of progression (adjusted HR 0.56; 95% CI 0.37–0.85; p = 0.004). The Mayo Imaging Classification remained independently predictive of renal outcomes (p = 0.027). Conclusions: This large real-world multicenter cohort highlights the geographically heterogeneous study-based burden of ADPKD across participating regions of Türkiye. Increasing prevalence over time likely reflects improved disease recognition, whereas the relatively low study-based prevalence suggests persistent under-recognition of ADPKD. These findings provide important longitudinal outcome data from an underrepresented population and support the need for earlier detection and improved risk stratification in ADPKD.

  • Open Access

    Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort

    by Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.


  • Fear, Anxiety, and Obsession Levels of Dialysis Patients and Healthy Individuals During the COVID-19 Pandemic

    by Arife Albayrak Coşar, Sibel YücEl Koçak, Filiz Turan, Arzu ÖztürK, MürVet Yılmaz

  • The role of calcitonin gene‐related peptide and substance P in the pathogenesis of dialysis headache

    by Gizem Gürsoy, Serhat Karadağ, Şennur Köse, Tamer Şakacı, Sibel Yücel Koçak, Yasemin Erdoğan Döventaş, Ayla Çulha Oktar, Muhammet Duran Bayar

    Aim: The present study aims to establish the role of serum CGRP and SP levels in the disease pathophysiology in patients with dialysis headache not accompanied by primary or secondary headaches, and also whether there is a correlation between these vasoactive peptides and the severity of headache.Method: This study was designed as prospective and multicenter. A total of 30 dialysis headache patients and 30 patients without headache as the control group in the Nephrology outpatient clinics which implement similar dialysis procedures were included in the study. Blood samples were taken from all the patients before hemodialysis, and post‐hemodialysis samples were collected. CGRP and SP contents in serum samples were measured using the ELISA method with detection kits.Results: A total of 60 patients were included in the study with 17 female and 13 male patients in the dialysis headache group and 18 female and 12 male patients in the control group, and there were no significant differences in sex and age between the groups. CGRP levels in the headache group were found to be significantly higher compared with the control group both before and after hemodialysis. Furthermore, pre‐hemodialysis CGRP levels were significantly higher than post‐hemodialysis CGRP levels in both the headache and control groups. Serum SP levels in the headache group were found to be higher compared with the control group both before and after hemodialysis, there was no significant difference between the groups. Even though SP levels in both groups decreased after hemodialysis, there was again no significant difference between the groups. No correlation was found between the patients' severity of headache and serum CGRP and SP levels.Conclusion: This study concludes that CGRP and SP, even though the latter is not statistically significant, play a role in the pathophysiology of the dialysis headache, and further studies with a larger and more specific patient population may reveal the relationship between the neuropeptides and dialysis headache more clearly.


  • Comparison of bone mineral density and biochemical factors in hemodialysis and peritoneal dialysis patients

    by Sibel Yucel Kocak, Arzu Ozdemir

    Aim: The aim of the study is to assess and compare the level of bone mineral density (BMD) in the patients undergoing hemodialysis (HD) and peritoneal dialysis (PD) and to identify risk factors related to low BMD. Materials and methods: scans were performed in 34 HD patients and 47 PD patients. Serum levels of albumin, (ALP), intact parathyroid hormone (I-PTH), and 25-hydroxy (OH) vitamin D were recorded for the prediction of BMD loss. Results: pared, only calcium levels differed between the group in such that HD patients had lower calcium compared with patients on PD (p = 0.001). The overall prevalence of osteoporosis (OP) among all participants was 27%. There was a negative correlation between femur neck BMD and age (r = -554, p = 0.007), and BMI (r = -555, p = 0.007). Diabetic nephropathy was the only etiology associated with decreased BMD at the femoral site (p = 0.027). There was a positive correlation between the serum albumin and BMD of lumbar spine (LS) (r = 585, p = 0.004). Bone mass of any site did not correlate with the dialysis type, duration of dialysis, and other biochemical markers like of OP and osteopenia are high in dialysis pa tients, with no difference between patients on regular HD and PD. Bone mass loss is re-lated to older age, higher BMI, and lower serum albumin level. DEXA measurement is necessary to monitor bone loss and timely treatment of OP in dialysis patients.


  • Daily variability of acid-base status and determinants of serum bicarbonate in hemodialysis patients

    by Arzu Ozdemir, Sibel Yucel Kocak, Suheyla Apaydä±N, Murvet Yä±Lmaz

    We aimed to evaluate daily variability of bicarbonate in hemodialysis (HD) patients and identify the factors which affect that issue. Blood samples of 41 patients for bicarbonate (total carbon dioxide (CO2)) and blood gas analysis (pH, bicarbonate (HCO3-)) were obtained, pre-dialysis and post-dialysis, on the first, second, and third session of the week. Those with pre-dialysis HCO3- < 22 mmol/L in all sessions were classified as acidotic. Demographic and laboratory data of acidotic and non-acidotic groups were compared, and the factors related to HCO3- level were identified. pH, tCO2, HCO3- of the first HD session were significantly lower than those of short inter-dialytic intervals (p < 0.001, respectively). Using Blant Altman analysis, pre- and post-dialysis tCO2 did not show good agreement with HCO3-. Acidotic patients had higher levels of serum albumin and phosphorus (p < 0.01 and p = 0.02, respectively) and were more likely to use sevelamer (p = 0.04). Also, the value of HCO3- was inversely correlated with dialysis vintage (r = -0.432, p = 0.005) and serum albumin (r = -0.427, p = 0.005). Since tCO2 did not show good agreement with HCO3-, relying solely on the pre-dialysis tCO2 values to define metabolic acidosis may increase misclassification rate. More work is needed for optimal assessment of acid-base status. Also, understanding the determinants of HCO3- may guide physicians for individualized HCO3- prescription.